Public Health England’s (PHE’s) vaccine evaluation expertise includes research and development, through the setting of standards for measuring the potency of an individual’s response to a specific vaccine (or vaccine candidate), to advising on the procurement of approved vaccines, the implementation of national immunisation schedules, and the continuous monitoring and surveillance of vaccine effectiveness. PHE vaccine development services has the scientific credibility and regulatory expertise to offer comprehensive pre-clinical and clinical vaccine development services to support UK government, UK and international academic partners, and the global vaccine industry. We also provide consultancy on method feasibility, development, validation, and technology transfer. Our core capabilities support:
• research into novel vaccines
• Identification and characterisation of novel vaccine candidates
• Method and formulation assessment
• Assay development and validation
• Specialist clinical trial serology
• Independent evaluation of vaccine efficacy
• Stability and release testing
Our highly skilled and experienced scientific project teams can evaluate both efficacy and quality at various stages of the manufacturing process, including final product release. We also have the capacity to provide continued evaluation throughout the product lifecycle. Pre-clinically, we can support vaccine formulation, packaging selection, and immunogenicity and potency testing, and we also have considerable experience of delivering product testing bundles to support formal product stability and/or release testing programmes.
Working closely with customers, we can also efficiently and cost-effectively deliver bespoke product testing packages to pre-defined regulatory standards in our state of the art GxP laboratories in two key locations i.e. our Immunoassay Laboratory (Salisbury, UK), and our Vaccine Evaluation Unit (Manchester, UK).